Home  Partnering Key areas of partnering interest
|
|
| Key areas of partnering interest |
|
|
Our research in this field is focused on neurological diseases, psychiatric disorders, and pain and anaesthesia. | Psychiatry |
|---|
Schizophrenia
- Novel therapeutics targeting psychosis with clinical proof of concept
- Novel therapeutics targeting cognition
- 3rd generation anti-psychotic
Depression/anxiety
- MT-1/2 agonist (phase II/III)
- Triple re-uptake inhibitor (serotonin / norepinephrine / dopamine)
- 1st generation CRF-1 antagonist (phase II/III)
- Novel diagnostic tools
- Novel biomarkers and genetic markers
- Novel ligands for in-vivo occupancy and PET imaging |
Neurology |
|---|
- Symptomatic treatment agents superior to AChE inhibitors
- Decrease of amyloid beta - small molecules approach
- Inhibitors of tau phosphorylation |
Analgesia |
|---|
Novel therapeutics for chronic pain (both neuropathic and
nociceptive) with particular interest in:
- Peripheral ion channels modulators:
- Novel channel targets and platform technologies
- VR1 antagonists
- Sodium channel (NaV 1.7, 1.8) blockers
- Calcium channel modulation
- Potassium channel modulation
- Monoamine modulators
- CCR2 antagonists
- Bradykinin receptor (B1) antagonists
- mPGES inhibitors
- Novel diagnostic clinical tools
- Novel biomarkers and genetic biomarkers
- Therapies with clinical proof of concept
|
jit.patel@astrazeneca.com
Psychiatry pre-clinical and technology. Analgesia
Hans.Hultberg@astrazeneca.com
Neurology
jeff.witcher@astrazeneca.com
Analgesia clinical/later stage
mark.odorisio@astrazeneca.com
Psychiatry clinical/later stage
|
|
|
|